Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3767-3772

  Nakadate, Megumi ^a,f   Yamazaki, Koichi ^a,f   Konishi, Jun ^a,f   Kinoshita, Ichiro ^b,f   Sukoh, Noriaki ^c,f   Harada, Masao ^c,f   Akie, Kenji ^d,f   Ogura, Shigeaki ^d,f   Ishida, Takashi ^e,f   Munakata, Mitsuru ^e,f   Dosaka Akita, Hirotoshi ^b,f   Isobe, Hiroshi ^c,f   Nishimura, Masaharu ^a,f  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d SAPPORO CITY GENERAL HOSPITAL   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^f Hokkaido Lung Cancer Clinical Research Group   (Japan)

Author keywords

Carboplatin; Chemotherapy; Non small cell lung cancer; Paclitaxel; Phase II study

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DYSPNEA; FEMALE; FEVER; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MOTOR NEUROPATHY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33750690660     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jamal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Mortality from malignant neoplasms by site in Japan. In: Cancer Statistics in Japan. Tokyo: Foundation for Promotion of Cancer Research, pp. 12, 2005.
3. Manfredi JJ, Parness J and Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94: 688-696, 1989.
4. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
6. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 19: 3210-3218, 2001.
7. Belani CP, Natale RB and Lee JS: Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 455a (abstr 1751), 1998.
8. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D et al: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21: 2933-2939, 2003.
9. Hirabayashi M, Okuda M, Endo K, Teramachi M, Yamaguchi K, Moriyama M et al: Dose finding study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer. Jpn J Cancer 41: 767-772, 2001 (in Japanese).
10. Kikuchi J, Yamazaki K, Kinoshita I, Asahina H, Imura M, Kikuchi E et al: Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer. Jpn J Clin Oncol 34: 505-509, 2004.
11. Bookman MA, Kloth DD, Kover PE, Smolinski S and Ozols RF: Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8: 611-614, 1997.
12. Klaasen U, Wilke H, Strumberg D, Eberhardt W, Korn M and Seeber S: Phase I study with a weekly 1 hour infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A: 547-549, 1996.
13. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
14. Cockroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
16. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
17. National Cancer Institute-Common Toxicity Criteria (NCI-CTC Version 2.0. April 30, 1999).
18. Simon R: Optimal two-stage designs for phase II clinical trials. Contr Clin Trials 10: 1-10, 1989.
19. Hirabayashi M, Endoh K, Teramachi M, Okuda M, Yamaguchi K, Fukuda K et al: Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study. Lung cancer 44: 355-362, 2004.
20. Fabi A, Barduagni M, Ferraresi V, Cortesi E, Gamucci T, Marinis FD et al: The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. J Exp Clin Cancer Res 23: 25-32, 2004.
21. Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hencing TA et al: A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 17: 104-109, 2006.
22. Belani CP, Larocca R, Rinaldi D, Tester W, Gable P and Perry M: A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel. Proc Am Soc Clin Oncol 23: 619, 2004.
23. Akerley III W, Glantz M and Choy H: Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Semin Oncol 23: 14-18, 1996.
24. Lopes NM, Adams EG, Pitts TW and Bhuyan BK: Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235-242, 1993.
25. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H and Wilson L: Mitotic block induced in HeLa cells by low concentration of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825, 1996.
26. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190, 1995.
27. Gilewski T and Norton L: Cytokinetics and breast cancer chemotherapy. Diseases of the Breast. Philadelphia. PA. Lippincott-Raven, pp. 751-768, 1996.
28. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P et al: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16: 153-158, 1998.
29. Marchetti P, Urien S, Cappellini GA, Ronzino G and Ficorella C: Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 44: S3-S13, 2002.
30. Rowinsky EK and Donehower RC: Drug therapy: Paclitaxel (Taxol). N Eng J Med 332: 1004-1014, 1995.